Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT06711978
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
66 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
CIPN
CIPN - Chemotherapy-Induced Peripheral Neuropathy
CIPN in Adjuvant Breast Cancer Patients
Duloxetine
Mirogabalin
RECRUITING
NCT06533826
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
357 Enrollment(s)
11 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


HER2-low Breast Cancer


Metastatic Breast Cancer


HER2-negative Breast Cancer
NOT_YET_RECRUITING
NCT07785856
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer
27 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
T-dxd Resistant HER2-Positive


HER2 Low Metastatic Breast Cancer
TERMINATED
NCT03820947
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
506 Enrollment(s)
32 Study location(s)
INTERVENTIONAL (NA)
Venous Reflux
NOT_YET_RECRUITING
NCT07782086
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
30 Enrollment(s)
14 Study location(s)
INTERVENTIONAL (NA)
Breast Cancer
COMPLETED
NCT07778407
TDXD in Metastatic HER2-Positive Breast Cancer
25 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Breast Advanced Malignancies
RECRUITING
NCT07459673
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
60 Enrollment(s)
7 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


HER2-positive Breast Cancer


Breast Cancer Stage IV
ACTIVE_NOT_RECRUITING
NCT05993234
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
257 Enrollment(s)
39 Study location(s)
OBSERVATIONAL (None)
HER2-positive Advanced Gastric Cancer


HER2-positive Gastroesophageal Junction Adenocarcinoma